BACKGROUND Hidradenitis suppurativa (HS) is characterized by recurrent, painful nodules in flexural areas. OBJECTIVE The objective of this study was to explore the placebo response in HS randomized clinical trials and to compare it briefly with the placebo response in psoriasis and atopic dermatitis. METHODS A Cochrane Review on interventions in HS was used as a starting point, and a systematic review was then undertaken by using the PubMed database, yielding 7 HS randomized clinical trials for inclusion in this study. RESULTS This review demonstrates that there is a robust placebo response in HS that is most marked in physical signs but also marked in pain responses. LIMITATIONS Multiple outcome measures utilized in these studies and reporting bias limited this review. CONCLUSION This large placebo response has implications for clinical trial design. This knowledge can also help deliver improved clinical care by forming the basis of nonpharmacologic treatments and help optimize current medication use to maximize the placebo effect.

中文翻译：

---

探索化脓性汗腺炎随机临床试验中安慰剂治疗组的变化：系统评价。

背景技术化脓性汗腺炎（HS）的特征在于弯曲区域中复发性疼痛结节。目的本研究的目的是探讨HS随机临床试验中的安慰剂反应，并将其与牛皮癣和特应性皮炎中的安慰剂反应进行简要比较。方法以Cochrane评估HS干预为起点，然后使用PubMed数据库进行系统综述，得出7项HS随机临床试验纳入本研究。结果该评价表明，HS中有强烈的安慰剂反应，其在体征上最为明显，但在疼痛反应中也最为明显。局限性这些研究中使用的多种结局指标和报告偏倚限制了本评价。结论这种大的安慰剂反应对临床试验设计有影响。这些知识还可以通过形成非药物治疗的基础来帮助提供更好的临床护理，并帮助优化当前的药物使用以最大化安慰剂的作用。